These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35253097)

  • 21. A review of the safety and efficacy of current COVID-19 vaccines.
    Huang Z; Su Y; Zhang T; Xia N
    Front Med; 2022 Feb; 16(1):39-55. PubMed ID: 35122210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired immunity against SARS-CoV-2 infection and vaccination.
    Renia L; Ng LF
    EMBO Mol Med; 2023 Dec; 15(12):e16345. PubMed ID: 37966373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The global epidemic of SARS-CoV-2 variants and their mutational immune escape.
    Tian D; Sun Y; Zhou J; Ye Q
    J Med Virol; 2022 Mar; 94(3):847-857. PubMed ID: 34609003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
    Noor R
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    Nambulli S; Escriou N; Rennick LJ; Demers MJ; Tilston-Lunel NL; McElroy AK; Barbeau DJ; Crossland NA; Hoehl RM; Schrauf S; White AG; Borish HJ; Tomko JA; Frye LJ; Scanga CA; Flynn JL; Martin A; Gerke C; Hartman AL; Duprex WP
    J Virol; 2024 May; 98(5):e0176223. PubMed ID: 38563762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
    Liu Q; Qin C; Liu M; Liu J
    Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The way of SARS-CoV-2 vaccine development: success and challenges.
    Dong Y; Dai T; Wang B; Zhang L; Zeng LH; Huang J; Yan H; Zhang L; Zhou F
    Signal Transduct Target Ther; 2021 Nov; 6(1):387. PubMed ID: 34753918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape.
    Lou F; Li M; Pang Z; Jiang L; Guan L; Tian L; Hu J; Fan J; Fan H
    Front Immunol; 2021; 12():744242. PubMed ID: 34804024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relevance of immune response and vaccination strategies of SARS-CoV-2 in the phase of viral red queen dynamics.
    Jacob JJ; John Fletcher G; Monisha Priya T; Veeraraghavan B; Mutreja A
    Indian J Med Microbiol; 2021; 39(4):417-422. PubMed ID: 34454775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Miyamoto S; Suzuki T
    Vaccine; 2024 Feb; 42(6):1401-1406. PubMed ID: 38310015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunity to SARS-CoV-2 induced by infection or vaccination.
    Castro Dopico X; Ols S; Loré K; Karlsson Hedestam GB
    J Intern Med; 2022 Jan; 291(1):32-50. PubMed ID: 34352148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 transmissibility compared between variants of concern and vaccination status.
    Wang L; Didelot X; Bi Y; Gao GF
    Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35062017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
    Gonzalez Lopez Ledesma MM; Sanchez L; Ojeda DS; Oviedo Rouco S; Rossi AH; Varese A; Mazzitelli I; Pascuale CA; Miglietta EA; Rodríguez PE; Pallarés HM; Costa Navarro GS; Caramelo JJ; Rothlauf PW; Liu Z; Bloyet LM; Cornejo Pontelli M; Rasetto NB; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Bianchimano L; Ríos AS; Treffinger Cienfuegos MS; Rodriguez García DR; Longueira Y; Laufer N; Alvarez D; Ceballos A; Ochoa V; Monzani C; Turk G; Salvatori M; Carradori J; Prost K; Rima A; Varela C; Ercole R; Toro RI; Gutierrez S; Zubieta M; Acuña D; Nabaes Jodar MS; Torres C; Mojsiejczuk L; Viegas M; Velazquez P; Testa C; Kreplak N; Yanovsky M; Whelan S; Geffner J; Pifano M; Gamarnik AV
    mBio; 2022 Feb; 13(1):e0344221. PubMed ID: 35073758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular and Clinical Epidemiology of SARS-CoV-2 Infection among Vaccinated and Unvaccinated Individuals in a Large Healthcare Organization from New Jersey.
    Mediavilla JR; Lozy T; Lee A; Kim J; Kan VW; Titova E; Amin A; Zody MC; Corvelo A; Oschwald DM; Baldwin A; Fennessey S; Zuckerman JM; Kirn T; Chen L; Zhao Y; Chow KF; Maniatis T; Perlin DS; Kreiswirth BN
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.